PTPI
Petros Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-07
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.07
P/S
0.23
EV/EBITDA
0.50
DCF Value
$-2.87
FCF Yield
-2931.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
63.5%
Operating Margin
-1844.6%
Net Margin
-968.2%
ROE
304.1%
ROA
-114.5%
ROIC
-397.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $0.00 | $-922.7K | $-0.03 |
| Q2 2025 | $0.00 | $5.4M | $-1.29 |
| Q1 2025 | $0.00 | $-2.3M | $-9.37 |
| Q4 2024 | $725.4K | $-9.3M | $-0.13 |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.66
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.